#TDM1 is effective and safe for metastatic #HER2PositiveBreastCancer after #pyrotinib and/or trastuzumab–pertuzumab failure, with low cancer cell cycle activity and activated macrophages/CD8⁺ T cells predicting treatment response.

#OpenAccess in #STTT: doi.org/10.1038/s413...